Payment overview · 2025
General Payments
$2,639.54
130 reported records · 39 companies
Healthcare provider profile · identity verified
Raymond Elsoueidi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · HAZARD, KY · NPI 1033348768
Verified facts
What the public records show
CMS Open Payments records show Raymond Elsoueidi, M.D. received $2,639.54 in general payments during 2025 across 130 reported records.
PFIZER INC. accounted for 10.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 72 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Bosulif, Cabometyx, Erleada, Keytruda, Padcev, Tecentriq.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUPRON DEPOT as an associated drug or biological on 6475 records involving 3205 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Lupron Depot by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOSULIF as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Bosulif by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PADCEV as an associated drug or biological on 40 records involving 37 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Padcev by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Padcev as an associated drug or biological on 3451 records involving 2301 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Padcev by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMFINZI as an associated drug or biological on 14406 records involving 6935 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Imfinzi by this doctor in 2024.
Exelixis Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABOMETYX as an associated drug or biological on 11749 records involving 4526 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Cabometyx by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Alecensa as an associated drug or biological on 194 records involving 149 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Alecensa by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Avastin as an associated drug or biological on 14 records involving 13 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Avastin by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rituxan as an associated drug or biological on 61 records involving 21 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rituxan by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tecentriq as an associated drug or biological on 3585 records involving 2526 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Tecentriq by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ERLEADA as an associated drug or biological on 32382 records involving 10919 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Erleada by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KEYTRUDA as an associated drug or biological on 46588 records involving 15767 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Keytruda by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOSULIF as an associated drug or biological on 3017 records involving 2109 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Bosulif by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PADCEV as an associated drug or biological on 9636 records involving 4430 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Padcev by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $263.74 | 10.0% | 15 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $239.04 | 9.1% | 12 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $182.38 | 6.9% | 12 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $167.52 | 6.3% | 9 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $163.09 | 6.2% | 8 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $152.19 | 5.8% | 8 | 2025 |
| La Jolla Pharmaceutical Company | Unresolved — no canonical attribution shown | $125.00 | 4.7% | 1 | 2025 |
| SEAGEN INC. | Unresolved — no canonical attribution shown | $95.00 | 3.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $91.77 | 3.5% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $81.93 | 3.1% | 4 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $81.06 | 3.1% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $75.84 | 2.9% | 4 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $69.09 | 2.6% | 4 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $61.24 | 2.3% | 3 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $56.20 | 2.1% | 3 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $51.91 | 2.0% | 2 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $50.53 | 1.9% | 3 | 2025 |
| Kite Pharma, Inc. | Unresolved — no canonical attribution shown | $49.87 | 1.9% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $48.46 | 1.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.58 | 1.8% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $41.73 | 1.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.53 | 1.4% | 2 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $35.86 | 1.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.25 | 1.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $32.96 | 1.2% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $32.32 | 1.2% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $32.02 | 1.2% | 2 | 2025 |
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.50 | 1.1% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.99 | 1.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.52 | 0.9% | 1 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $21.02 | 0.8% | 1 | 2025 |
| BeiGene USA, Inc. | Unresolved — no canonical attribution shown | $20.40 | 0.8% | 1 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $19.73 | 0.8% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $18.51 | 0.7% | 1 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $18.32 | 0.7% | 1 | 2025 |
| ADC THERAPEUTICS AMERICA, INC. | Unresolved — no canonical attribution shown | $17.47 | 0.7% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.43 | 0.7% | 1 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $14.66 | 0.6% | 1 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $13.88 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,532.12 | 128 |
| Education | $107.42 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $163.09 | 8 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $152.19 | 8 | 2025 |
Source payment records
|
|||||
| ZEVTERA Normalized: zevtera |
Drug | La Jolla Pharmaceutical Company | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $96.19 | 5 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $92.41 | 5 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological, Drug | Astellas Pharma US Inc, PFIZER INC. | $85.76 | 6 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $82.86 | 5 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | Astellas Pharma US Inc, PFIZER INC. | $81.67 | 4 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $81.06 | 3 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $71.33 | 4 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $69.09 | 4 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Biological, Drug | ABBVIE INC., Genentech USA, Inc. | $66.43 | 3 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $61.24 | 3 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $61.02 | 3 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $59.95 | 3 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $56.95 | 3 | 2025 |
Source payment records
|
|||||
| BOSULIF Normalized: bosulif |
Drug | PFIZER INC. | $56.95 | 3 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $56.95 | 3 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $54.57 | 3 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Merck Sharp & Dohme LLC | $52.91 | 3 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $51.91 | 2 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $51.91 | 2 | 2025 |
Source payment records
|
|||||
| Yescarta Normalized: yescarta |
Drug | Kite Pharma, Inc. | $49.87 | 3 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $47.23 | 4 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC., Genmab U.S., Inc. | $46.99 | 3 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC. | $45.04 | 2 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $45.04 | 2 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $44.16 | 2 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $43.50 | 2 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $43.50 | 2 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $43.23 | 2 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $43.13 | 1 | 2025 |
Source payment records
|
|||||
| LUTATHERA Normalized: lutathera |
Drug | Novartis Pharmaceuticals Corporation | $41.52 | 3 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc., BeiGene USA, Inc. | $40.13 | 2 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $37.42 | 2 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $35.86 | 2 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $35.86 | 2 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $35.86 | 2 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $34.25 | 2 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $32.96 | 2 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $32.02 | 2 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $30.84 | 1 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $27.06 | 1 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $27.06 | 1 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $26.56 | 2 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $25.99 | 1 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $25.39 | 2 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| XALKORI Normalized: xalkori |
Drug | ARRAY BIOPHARMA INC | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological | GENZYME CORPORATION | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| Tivdak Normalized: tivdak |
Drug | Genmab U.S., Inc. | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| Xofigo Normalized: xofigo |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| Tecentriq Normalized: tecentriq |
Biological | Genentech USA, Inc. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| NINLARO Normalized: ninlaro |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| ZYNLONTA Normalized: zynlonta |
Drug | ADC THERAPEUTICS AMERICA, INC. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| EMRELIS Normalized: emrelis |
Drug | ABBVIE INC. | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $13.88 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $8.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOSULIF bosulif |
2025 | Bosulif | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CABOMETYX cabometyx |
2025 | Cabometyx | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ERLEADA erleada |
2025 | Erleada | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KEYTRUDA keytruda |
2025 | Keytruda | 2024 | 79 | exact normalized | Medicare Part D |
| PADCEV padcev |
2025 | Padcev | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Tecentriq tecentriq |
2025 | Tecentriq | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUPRON DEPOT open payments reported associated product |
CMS Open Payments — General Payments 6475 supporting records · 3205 recipient NPIs · example record 1201352804 |
Lupron Depot · 2024 Exact normalized brand match · 1 Part D row |
37 | 16 |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | BOSULIF open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1228863907 |
Bosulif · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | PADCEV open payments reported associated product |
CMS Open Payments — General Payments 40 supporting records · 37 recipient NPIs · example record 1228863907 |
Padcev · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Padcev open payments reported associated product |
CMS Open Payments — General Payments 3451 supporting records · 2301 recipient NPIs · example record 1238560690 |
Padcev · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | IMFINZI open payments reported associated product |
CMS Open Payments — General Payments 14406 supporting records · 6935 recipient NPIs · example record 1206131578 |
Imfinzi · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Exelixis Inc. Exact reporting entity; no affiliate inference |
2025 | CABOMETYX open payments reported associated product |
CMS Open Payments — General Payments 11749 supporting records · 4526 recipient NPIs · example record 1218789893 |
Cabometyx · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Alecensa open payments reported associated product |
CMS Open Payments — General Payments 194 supporting records · 149 recipient NPIs · example record 1211488956 |
Alecensa · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Avastin open payments reported associated product |
CMS Open Payments — General Payments 14 supporting records · 13 recipient NPIs · example record 1211492409 |
Avastin · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Rituxan open payments reported associated product |
CMS Open Payments — General Payments 61 supporting records · 21 recipient NPIs · example record 1211490411 |
Rituxan · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Tecentriq open payments reported associated product |
CMS Open Payments — General Payments 3585 supporting records · 2526 recipient NPIs · example record 1211488420 |
Tecentriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | ERLEADA open payments reported associated product |
CMS Open Payments — General Payments 32382 supporting records · 10919 recipient NPIs · example record 1174257499 |
Erleada · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | KEYTRUDA open payments reported associated product |
CMS Open Payments — General Payments 46588 supporting records · 15767 recipient NPIs · example record 1237992210 |
Keytruda · 2024 Exact normalized brand match · 1 Part D row |
79 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | BOSULIF open payments reported associated product |
CMS Open Payments — General Payments 3017 supporting records · 2109 recipient NPIs · example record 1228795613 |
Bosulif · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PADCEV open payments reported associated product |
CMS Open Payments — General Payments 9636 supporting records · 4430 recipient NPIs · example record 1228794152 |
Padcev · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 129 | 39 |
| Anastrozole | Anastrozole | 107 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 86 | 45 |
| Keytruda | Pembrolizumab | 79 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 70 | 21 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 53 | 33 |
| Hydroxyurea | Hydroxyurea | 47 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 45 | 15 |
| Prednisone | Prednisone | 44 | 11 |
| Revlimid | Lenalidomide | 43 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 41 | 13 |
| Lupron Depot | Leuprolide Acetate | 37 | 16 |
| Padcev | Enfortumab Vedotin-Ejfv | 37 | suppressed |
| Gabapentin | Gabapentin | 34 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 33 | 16 |
| Imfinzi | Durvalumab | 28 | suppressed |
| Bortezomib | Bortezomib | 27 | suppressed |
| Bosulif | Bosutinib | 26 | suppressed |
| Kyprolis | Carfilzomib | 26 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Velcade | Bortezomib | 21 | suppressed |
| Letrozole | Letrozole | 19 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 19 | 11 |
| Potassium Chloride | Potassium Chloride | 19 | 12 |
| Clonazepam | Clonazepam | 17 | suppressed |
| Lenalidomide | Lenalidomide | 17 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 16 | suppressed |
| Tecentriq | Atezolizumab | 16 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 14 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Erleada | Apalutamide | 14 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 14 | suppressed |
| Rituxan | Rituximab | 14 | suppressed |
| Xgeva | Denosumab | 14 | suppressed |
| Alecensa | Alectinib Hcl | 13 | suppressed |
| Avastin | Bevacizumab | 13 | suppressed |
| Procrit | Epoetin Alfa | 13 | suppressed |
| Cabometyx | Cabozantinib S-Malate | 12 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,639.54 · 130 records | PFIZER INC. | ADCETRIS, AYVAKIT, BESREMI, BLENREP, BOSULIF, BRAFTOVI, BRUKINSA, CABOMETYX, CARVYKTI, DARZALEX, DATROWAY, ELREXFIO, EMRELIS, EPKINLY, ERLEADA, Enhertu, FRUZAQLA, Fabhalta, IBRANCE, IMBRUVICA, INLYTA, INQOVI, JAKAFI, JAYPIRCA, JEMPERLI, KEYTRUDA, KEYTRUDA QLEX, KISQALI, LIBTAYO, LONSURF, LORBRENA, LUTATHERA, LYNPARZA, Lenvima, MEKTOVI, MI CANCER SEEK, MONJUVI, NERLYNX, NINLARO, Nubeqa, OPDIVO, ORGOVYX, Onivyde, Orserdu, PADCEV, PLUVICTO, PYRUKYND, REBLOZYL, RYBREVANT, SARCLISA, SCEMBLIX, Stivarga, TAGRISSO, TALVEY, TALZENNA, TECVAYLI, TUKYSA, Tecentriq, Tivdak, Trodelvy, VENCLEXTA, VERZENIO, Vyloy, WELIREG, XALKORI, XTANDI, Xofigo, Yescarta, ZEJULA, ZEVTERA, ZYNLONTA, ZYNYZ | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Bosulif play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error